Moody National Bank Trust Division Sells 21,093 Shares of Pfizer Inc. $PFE

Moody National Bank Trust Division reduced its stake in Pfizer Inc. (NYSE:PFE) by 20.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,052 shares of the biopharmaceutical company’s stock after selling 21,093 shares during the period. Moody National Bank Trust Division’s holdings in Pfizer were worth $2,043,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer in the third quarter valued at $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer during the second quarter worth approximately $30,000. True Wealth Design LLC boosted its holdings in shares of Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Pfizer during the 2nd quarter worth approximately $32,000. Finally, Sagard Holdings Management Inc. acquired a new stake in Pfizer during the 2nd quarter valued at $36,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst upgrade: Guggenheim raised its price target to $36 and reiterated a Buy, signaling sizable upside vs. current levels and supporting bullish investor sentiment. Article Title
• Positive Sentiment: Lyme vaccine efficacy: Pfizer and Valneva reported >70% efficacy in the Phase 3 VALOR trial — the result bolsters Pfizer’s vaccine pipeline and longer‑term revenue optionality if regulators approve the shot. Article Title
• Positive Sentiment: Oncology progress highlighted by management: CFO Dave Denton discussed recent oncology milestones on NYSE Live, reinforcing the narrative that new oncology assets could drive growth beyond legacy franchises. Article Title
• Positive Sentiment: Bullish research/coverage: Several outlets and analysts (Seeking Alpha, 247wallst, The Motley Fool coverage) are calling a turnaround and higher targets for PFE based on pipeline momentum and valuation, which supports buying interest. Article Title
• Neutral Sentiment: Investor events: Pfizer scheduled a May 5 webcast to discuss Q1 results and a first‑quarter performance report — gives investors a formal update and a clear date to reassess fundamentals. Article Title
• Negative Sentiment: Trial missed primary endpoint: Although efficacy was strong, the VALOR trial failed to meet its prespecified primary statistical endpoint because fewer participants contracted Lyme disease than expected — this raises regulatory and labeling uncertainty that can delay or complicate approval. Article Title
• Negative Sentiment: Partner Valneva’s selloff: Valneva shares plunged after the announcement despite the efficacy readout, highlighting market concern about regulatory risk and commercial prospects; negative headlines around the partner can create near‑term volatility for Pfizer. Article Title

Pfizer Price Performance

NYSE PFE opened at $26.98 on Wednesday. The firm’s 50 day moving average is $26.75 and its 200-day moving average is $25.64. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $153.39 billion, a PE ratio of 19.83 and a beta of 0.47. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.63 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on PFE shares. Guggenheim increased their price objective on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. HSBC raised their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Bank of America dropped their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Finally, Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.19.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.